drugset / Trial / NCT03058900

Summary

An abnormal intestinal microbiota may be the mediator of the common inflammatory pathways seen in psoriatic arthritis. This study will explore clinical aspects associated with modifying the intestinal microbiota by infusing fecal donor microbiota into the small intestine of psoriatic arthritis patients with a minimum of three swollen joints despite at least three months of methotrexate treatment.

Timeline

Start
2017-05-16
Primary completion
2020-06-02
Completion
2020-06-02

Publications

Drugs

EvaluationDrugModalityDoseRoute
Subject Ornidazole Other / unclassified 50 g Other
Background Methotrexate Small molecule Subcutaneous

Indications